

# Min Shen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6328120/publications.pdf>

Version: 2024-02-01

34  
papers

2,383  
citations

516710

16  
h-index

395702

33  
g-index

41  
all docs

41  
docs citations

41  
times ranked

4776  
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science, 2020, 6, 672-683.	11.3	684
2	Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature, 2015, 522, 216-220.	27.8	336
3	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discovery, 2020, 6, 80.	6.7	172
4	Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nature Communications, 2015, 6, 6220.	12.8	168
5	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. ACS Pharmacology and Translational Science, 2020, 3, 1008-1016.	4.9	162
6	An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. ACS Pharmacology and Translational Science, 2020, 3, 997-1007.	4.9	95
7	Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. ACS Pharmacology and Translational Science, 2020, 3, 1165-1175.	4.9	94
8	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalinizing Small Molecules. ACS Infectious Diseases, 2021, 7, 1389-1408.	3.8	74
9	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research, 2015, 17, 59.	5.0	61
10	Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays. Scientific Reports, 2017, 7, 12758.	3.3	59
11	Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19. ACS Pharmacology and Translational Science, 2021, 4, 1124-1135.	4.9	40
12	Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space. ACS Central Science, 2018, 4, 1727-1741.	11.3	32
13	Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. Endocrine-Related Cancer, 2015, 22, 319-329.	3.1	28
14	Identification of ML251, a Potent Inhibitor of <i>T. brucei</i> and <i>T. cruzi</i> Phosphofructokinase. ACS Medicinal Chemistry Letters, 2014, 5, 12-17.	2.8	27
15	Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 1727-1739.	3.0	23
16	Structure activity relationships of human galactokinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 721-727.	2.2	20
17	Predictive models for estimating cytotoxicity on the basis of chemical structures. Bioorganic and Medicinal Chemistry, 2020, 28, 115422.	3.0	16
18	Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. ACS Medicinal Chemistry Letters, 2021, 12, 1267-1274.	2.8	16

#	ARTICLE	IF	CITATIONS
19	A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. <i>SLAS Discovery</i> , 2022, 27, 86-94.	2.7	16
20	Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 40, 127906.	2.2	15
21	Circulating immune/inflammation markers in Chinese workers occupationally exposed to formaldehyde. <i>Carcinogenesis</i> , 2015, 36, 852-857.	2.8	14
22	Discovery of novel inhibitors of human galactokinase by virtual screening. <i>Journal of Computer-Aided Molecular Design</i> , 2019, 33, 405-417.	2.9	14
23	Discovery and Optimization of 2-H <sup>2</sup> -Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4913-4946.	6.4	12
24	Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. <i>Chemical Science</i> , 2021, 12, 12600-12609.	7.4	11
25	Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 38, 116119.	3.0	8
26	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. <i>Journal of Biological Chemistry</i> , 2019, 294, 17654-17668.	3.4	6
27	Hybrid <i>In Silico</i> Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1675-1688.	4.9	6
28	Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. <i>ACS Infectious Diseases</i> , 2022, 8, 1191-1203.	3.8	4
29	Human GPR17 missense variants identified in metabolic disease patients have distinct downstream signaling profiles. <i>Journal of Biological Chemistry</i> , 2021, 297, 100881.	3.4	3
30	Discovery of Small-Molecule VapC1 Nuclease Inhibitors by Virtual Screening and Scaffold Hopping from an Atomic Structure Revealing Protein-Protein Interactions with a Native VapB1 Inhibitor. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 1249-1258.	5.4	3
31	Virtual Screening for the Discovery of Microbiome $\beta$ -Glucuronidase Inhibitors to Alleviate Cancer Drug Toxicity. <i>Journal of Chemical Information and Modeling</i> , 2022, , .	5.4	3
32	Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13551-13571.	6.4	2
33	Graph Convolutional Network-Based Screening Strategy for Rapid Identification of SARS-CoV-2 Cell-Entry Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 1988-1997.	5.4	1
34	Inside Cover: A Highly Potent and Selective Caspase-1 Inhibitor that Utilizes a Key 3-Cyanopropanoic Acid Moiety (ChemMedChem 5/2010). <i>ChemMedChem</i> , 2010, 5, 634-634.	3.2	0